Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Improving Immunotherapy for Chronic Viral Infections
Scientific Advances

Improving Immunotherapy for Chronic Viral Infections

By Anna WilliamsFeb 12, 2019
Share
Facebook Twitter Email
Pablo Penaloza-MacMaster, PhD, assistant professor of Microbiology-Immunology, was the principal investigator of the study, published in the journal PLOS Pathogens.

Northwestern Medicine scientists have identified a novel strategy that could improve the efficacy of immunotherapy in treating chronic viral infections.

Pablo Penaloza-MacMaster, PhD, assistant professor of Microbiology-Immunology, was the senior author of the study, which was published in the journal PLOS Pathogens.

Immune cells called T-cells are critical for controlling tumors and viruses. But during chronic viral infection — such as HIV and hepatitis C — T-cells eventually become exhausted.

Immunotherapy, which strengthens the body’s own immune system to fight diseases, has become increasingly important in the area of cancer treatment. In a form called immune checkpoint inhibitors, antibodies target proteins that act as “brakes” on T-cells, such as PD-1. Once PD-1 is blocked, the T-cells are freed to launch an immune attack.

But although PD-1 therapies are now used to treat certain types of cancer — and the upregulation of immune checkpoints like PD-1 is a hallmark of T-cell exhaustion — the therapies have so far shown limited benefit in treating chronic viral infections.

Recently, research has suggested that the microbiome can influence the efficiency of PD-1 therapies; it was unknown, however, which specific microbial products might be beneficial.

In the current study, the scientists evaluated whether lipopolysaccharide (LPS) — a molecule on the surface of gram-negative bacteria — might affect response to PD-1 therapy in an animal model of chronic viral infection.

The team discovered that low doses of bacterial LPS in mice triggered an immune pathway called TLR4, which when combined with PD-1 therapy, revitalized the exhausted T-cells.

“This combined therapy resulted in a striking enhancement of immune responses to the virus — significantly greater than PD-1 therapy alone,” Penaloza said. “Our study demonstrates that immune checkpoint therapy can be substantially improved by just adding one specific microbial molecule.”

The authors caution, however, that much more research is needed in this area, and it is not yet clear if these results could be safely translated to humans.

In ongoing research, Penaloza’s laboratory is investigating whether the combinatory treatment might also be beneficial in models of cancer, as PD-1 therapy is currently only effective in a limited percentage of cancer cases.

Penaloza is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Other Northwestern authors include graduate students Yidan Wang and Young Rock Chung.

The study was funded by a grant from the National Institutes of Health (1R21AI132848-01A1).

Immunology Microbiology Research
Share. Facebook Twitter Email

Related Posts

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Comments are closed.

Latest News

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220617_NM_0434
20220617_NM_0858
20220617_NM_0643
20220617_NM_0835
20220617_NM_0544
20220617_NM_0450
20220617_NM_0790
20220617_NM_0811
20220617_NM_0851
20220617_NM_0696
20220617_NM_0779
20220617_NM_0838

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.